Teva Pharmaceutical Industries Limited (TLV:TEVA)
9,840.00
-96.00 (-0.97%)
Jul 13, 2026, 5:26 PM IDT
Teva Pharmaceutical Industries Employees
As of December 31, 2025, Teva Pharmaceutical Industries had 32,842 total employees, including 31,173 full-time and 1,669 part-time employees. The number of employees decreased by 2,844 or -7.97% compared to the previous year.
Employees
32,842
Change
-2,844
Growth
-7.97%
Revenue / Employee
1.71M ILS
Profits / Employee
154.37K ILS
Market Cap
115.36B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 32,842 | -2,844 | -7.97% | 31,173 | 1,669 |
| Jun 30, 2025 | 37,000 | 0 | - | 37,000 | 0 |
| Mar 31, 2025 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2024 | 35,686 | -786 | -2.16% | 33,892 | 1,794 |
| Sep 30, 2024 | 37,000 | 528 | 1.45% | 37,000 | 0 |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% | 35,001 | 1,471 |
| Dec 31, 2022 | 35,125 | -854 | -2.37% | 34,004 | 1,121 |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% | 34,713 | 1,266 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kamada | 462 |
| Rekah Pharmaceutical Industry | 390 |
| InterCure | 285 |
| Together Pharma | 210 |
| Seach Medical Group | 162 |
| Tikun Olam-Cannbit Pharmaceuticals | 4 |
Teva Pharmaceutical Industries News
- 1 day ago - Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study - MarketBeat
- 4 days ago - Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
- 4 days ago - Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar - TheFly
- 4 days ago - Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Business Wire
- 4 days ago - Teva, Polpharma Biologics announce global licensing agreement - TheFly
- 4 days ago - Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ - TheFly
- 6 days ago - Teva Pharmaceutical Industries Transcript: Study result - Transcripts
- 6 days ago - Teva Pharmaceutical Industries Press release: Study result - Filings